Ah Young Lee

US Patent:

20190060424, Feb 28, 2019

Filed:

Sep 4, 2018

Appl. No.:

16/121273

Inventors:

- New York NY, US
Chang Won Kho - New York NY, US
Ah Young Lee - New York NY, US

International Classification:

A61K 38/50
C12Q 1/6883
C12N 7/00
C12N 15/86
A61K 48/00
A61K 38/17
A61K 31/7088
G01N 33/573

Abstract:

Methods for treating cardiovascular disease, and in particular heart failure, are provided comprising administering a therapeutically effective amount of a modulator of SERCA2a post-translation modification such as SUMOylation or acetylation. Also provided are methods of treating cardiovascular disease by inhibiting SERCA2a degradation. Further provided are methods of diagnosing a propensity to develop heart failure comprising determining if a SERCA2a mutant is present or determining the level of expression of SUMO1 in cardiomyocytes. The disclosure also provides methods of screening for therapeutics that modulate the post-translational modification of SERCA2a, such as by modulating post-translational SUMOylation and/or acetylation.

US Patent:

20180127407, May 10, 2018

Filed:

Nov 29, 2017

Appl. No.:

15/826238

Inventors:

- New York NY, US
Ah Young Lee - New York NY, US
Changwon Kho - New York NY, US
Roger J. Hajjar - Tenafly NJ, US

International Classification:

C07D 417/12
C07D 413/12
A61K 48/00
A61K 31/4245
C07D 413/04
A61K 31/433
A61K 31/428

Abstract:

Provided are SUMO activators, which can enhance SUMOylation of SERCA2a, which are useful in the treatment of heart failure, cardiovascular diseases, cancer, neurodegenerative disorders, viral infection, bacterial infection, liver disease, inflammation, and other diseases.

US Patent:

20170014494, Jan 19, 2017

Filed:

Sep 30, 2016

Appl. No.:

15/281269

Inventors:

- New York NY, US
Chang Won Kho - New York NY, US
Ah Young Lee - New York NY, US

International Classification:

A61K 38/50
A61K 48/00
C12Q 1/68
C12N 7/00
G01N 33/573
A61K 38/17
C12N 15/86

Abstract:

Methods for treating cardiovascular disease, and in particular heart failure, are provided comprising administering a therapeutically effective amount of a modulator of SERCA2a post-translation modification such as SUMOylation or acetylation. Also provided are methods of treating cardiovascular disease by inhibiting SERCA2a degradation. Further provided are methods of diagnosing a propensity to develop heart failure comprising determining if a SERCA2a mutant is present or determining the level of expression of SUMO1 in cardiomyocytes. The disclosure also provides methods of screening for therapeutics that modulate the post-translational modification of SERCA2a, such as by modulating post-translational SUMOylation and/or acetylation.

US Patent:

20150316551, Nov 5, 2015

Filed:

Jul 13, 2015

Appl. No.:

14/798357

Inventors:

Roger Joseph Hajjar - Tenafly NJ, US
Chang Won Kho - New York NY, US
Ah Young Lee - New York NY, US

Assignee:

Icahn School of Medicine at Mount Sinai - New York NY

International Classification:

G01N 33/573
C12Q 1/68

Abstract:

Methods for treating cardiovascular disease, and in particular heart failure, are provided comprising administering a therapeutically effective amount of a modulator of SERCA2a post-translation modification such as SUMOylation or acetylation. Also provided are methods of treating cardiovascular disease by inhibiting SERCA2a degradation. Further provided are methods of diagnosing a propensity to develop heart failure comprising determining if a SERCA2a mutant is present or determining the level of expression of SUMO1 in cardiomyocytes. The disclosure also provides methods of screening for therapeutics that modulate the post-translational modification of SERCA2a, such as by modulating post-translational SUMOylation and/or acetylation.

US Patent:

20150218148, Aug 6, 2015

Filed:

Aug 29, 2013

Appl. No.:

14/424289

Inventors:

- New York NY, US
Ah Young Lee - New York NY, US
Changwon Kho - New York NY, US
Roger J. Hajjar - Tenafly NJ, US

International Classification:

C07D 417/12
A61K 48/00
A61K 31/4245
C07D 413/12
A61K 31/428
A61K 31/433

Abstract:

Provided are SUMO activators, which can enhance SUMOylation of SERCA2a, which are useful in the treatment of heart failure, cardiovascular diseases, cancer, neurodegenerative disorders, viral infection, bacterial infection, liver disease, inflammation, and other diseases.

US Patent:

20140234287, Aug 21, 2014

Filed:

Jul 13, 2012

Appl. No.:

14/232105

Inventors:

Roger Joseph Hajjar - Tenafly NJ, US
Chang Won Kho - New York NY, US
Ah Young Lee - New York NY, US

Assignee:

Icahn School of Medicine at Mount Sinai - New York NY

International Classification:

A61K 38/50
G01N 33/573
C12Q 1/68
A61K 38/17

US Classification:

424 946, 514 44 R, 435 76, 435 618, 435 61, 435 613

Abstract:

Methods for treating cardiovascular disease, and in particular heart failure, are provided comprising administering a therapeutically effective amount of a modulator of SERCA2a post-translation modification such as SUMOylation or acetylation. Also provided are methods of treating cardiovascular disease by inhibiting SERCA2a degradation. Further provided are methods of diagnosing a propensity to develop heart failure comprising determining if a SERCA2a mutant is present or determining the level of expression of SUMO1 in cardiomyocytes. The disclosure also provides methods of screening for therapeutics that modulate the post-translational modification of SERCA2a, such as by modulating post-translational SUMOylation and/or acetylation.